Candel Therapeutics (CADL) Total Debt (2020 - 2025)

Candel Therapeutics has disclosed Total Debt across 6 years of filings, most recently posting $1.0 million for Q4 2025.

• Total Debt for Q4 2025 came in at $1.0 million, down 90.64% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.0 million (down 90.64% YoY), and the FY2025 annual result was $1.0 million, down 90.64% from the prior year.
• Total Debt came in at $1.0 million for Q4 2025 at Candel Therapeutics, down from $4.2 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $20.5 million in Q4 2023 to a low of $560000.0 in Q4 2021.
• The 5-year median for Total Debt is $10.7 million (2024), against an average of $11.6 million.
• Across the five-year window, Total Debt soared 3507.5% in 2022 and sank 90.64% in 2025, its largest moves.
• Candel Therapeutics' Total Debt stood at $560000.0 in 2021, then jumped by 3507.5% to $20.2 million in 2022, then rose by 1.6% to $20.5 million in 2023, then slumped by 47.55% to $10.8 million in 2024, then tumbled by 90.64% to $1.0 million in 2025.
• The last three Total Debt figures came in at $1.0 million (Q4 2025), $4.2 million (Q3 2025), and $6.7 million (Q2 2025), per Business Quant data.